Guide

Rights offering explained

Six months after its follow-on equity deal, Harbor Biotech needed another $95 million for a Phase 3 trial expansion. The board rejected a marketed overnight follow-on — the stock was down 22% from the prior raise and institutional investors were saturated. Instead, Harbor launched a rights offering: existing shareholders received one subscription right per share held, and every five rights entitled the holder to buy one new share at $38.40, a 12% discount to the $43.65 unaffected price. The theory was fair: let current owners maintain proportionate ownership at a preferential price.

Reality was messier. Only 62% of rights were exercised. Index funds and passive accounts routinely let rights lapse. Retail holders who missed the ex-rights date saw ownership diluted 9.4% while fully participating holders absorbed only 2.1% dilution. A standby underwriter purchased unsubscribed shares, charging a backstop fee that added $4.2 million to issuance cost. Rights traded briefly on Nasdaq under ticker HBRV until expiration, but bid-ask spreads were wide and volume thin. This guide explains how rights offerings work, the key dates and ratios, oversubscription mechanics, dilution math for participants versus non-participants, the Harbor Biotech walkthrough, a financing decision table, common pitfalls, and a shareholder checklist.

What is a rights offering?

A rights offering (also called a rights issue or preemptive offering) lets existing shareholders buy new shares before the company sells them to outsiders. Each holder receives subscription rights — transferable coupons, usually one per share owned on the record date. A subscription ratio defines how many rights are needed to buy one new share (Harbor: 5 rights = 1 share). The subscription price is set below market, typically 10–20% discount, to compensate holders for putting up fresh capital and to make exercise economically attractive.

Rights offerings are common in Europe and among REITs, banks, and distressed issuers in the US. They appeal when management wants to signal fairness to retail holders, when a full underwritten follow-on would face a steep discount, or when charter or regulatory rules require shareholder participation. They are slower and operationally heavier than shelf follow-ons but can raise capital without handing the entire allocation to a handful of institutions overnight.

Key dates and timeline

Announcement and record date

The company announces terms: size, ratio, subscription price, and expiration. The record date determines who receives rights. Only shareholders of record on that date get rights; buyers after the record date do not (unless they purchase shares with rights attached).

Ex-rights date

On the ex-rights date, the stock trades without the attached rights. Theory says the share price drops by the theoretical value of the right on ex-date. If a $43.65 stock offers a $38.40 subscription via a 5-for-1 ratio, the theoretical right value is roughly ($43.65 − $38.40) ÷ 5 ≈ $1.05; ex-rights price ≈ $42.60. Real markets deviate with volatility, borrow costs, and uncertainty about take-up.

Subscription period

Holders typically have 16–45 days to exercise, oversubscribe, or sell rights. Transfer agents mail instruction forms; brokers handle exercise through online portals. Expired, unexercised rights become worthless.

Settlement

New shares issue after the subscription period closes. If a standby backstop exists, the underwriter buys any unsubscribed portion at the subscription price (or a contractually defined price), ensuring the company raises the targeted gross proceeds.

Exercise, oversubscription, and standby backstop

Basic exercise

To exercise, a holder pays the subscription price per new share their rights entitle them to buy. Harbor holders with 500 shares received 500 rights, enough to buy 100 new shares at $38.40 each ($3,840 total). After exercise, they owned 600 shares and preserved their 0.24% stake in the expanded company (assuming all other holders also exercised pro rata).

Oversubscription privilege

Most US rights offers include an oversubscription privilege: holders who fully exercise may apply for additional shares if other holders lapse. Allocation is usually pro rata among oversubscribers. This lets attentive holders pick up extra stock at the discount when passive accounts expire rights — a feature Harbor’s IR team under-explained in press materials.

Standby underwriting

A standby underwriter (backstop) commits to purchase unsubscribed shares, guaranteeing proceeds to the issuer. The fee runs 2–5% of backstopped amount plus expenses — Harbor paid 3.25% on $36 million backstopped ($1.17M) plus a $3M flat commitment fee. Non-backstopped rights offers exist but risk raising less than targeted if take-up is weak.

Trading rights

Listed rights may trade separately for the subscription period. Selling rights realizes part of the discount value without putting up subscription cash; buying rights lets outsiders participate. Thin liquidity often means selling rights is worse than exercising or oversubscribing for holders who have capital available.

Dilution math: participate vs sit out

Rights offerings are often marketed as “non-dilutive if you participate.” That is only true pro rata. Let:

N = shares you hold before the offer
R = subscription ratio (rights per new share)
S = total new shares issued
T = total shares outstanding after the offer

If you exercise all rights, your post-offer shares = N + N/R = N(1 + 1/R). Your ownership = N(1 + 1/R) / T. If everyone exercises fully, T = old shares + S and each holder’s percentage is unchanged.

If you do not exercise, your ownership falls from N / (T − S) to N / T. Harbor example: 248 million shares pre-offer; the rights issue added 2.47 million new shares (62% take-up of a 3.98 million share maximum). A holder with 1,000 shares who did nothing went from 1,000 / 248,000,000 to 1,000 / 250,470,000 — a 0.99% relative ownership loss. Against a fully participating peer, the gap is larger because oversubscribers acquired extra discounted shares from lapsed rights; Harbor IR calculated non-participants lost 9.4% of economic interest versus full exercise plus oversubscription.

The subscription discount is not free money — it compensates for the new capital and the risk that lapsed rights dilute you. Compare the offer to buying stock in the open market after the deal: if you would not buy at the subscription price, exercising purely to avoid dilution may still be wrong for your portfolio.

Harbor Biotech walkthrough

Harbor filed a prospectus supplement for up to $153 million gross (3.98 million shares at $38.40) but sized the final deal at $95 million based on trial budget. Terms: 1 right per share, 5 rights per new share, 12% discount, 30-day subscription window, oversubscription allowed, BofA as standby at 3.25% backstop fee.

Take-up: 62% basic exercise, 8% additional via oversubscription, 30% lapsed. Backstop absorbed $36 million of unsubscribed stock. Gross proceeds $95 million; net ~$87.4 million after fees — higher cost of capital than the prior follow-on’s 4.1% gross spread on a fully subscribed deal.

Stock reaction: Announcement down 4% (dilution overhang); ex-rights drop matched theory within 1%; post-settlement flat as Phase 3 funding removed a binary overhang. Sell-side models that ignored lapsed-rights dilution to passive holders mis-forecasted Q3 share count by 1.1 million shares.

Lesson: Rights offerings protect shareholders who exercise but punish inattention. Issuers should model partial take-up, not 100% exercise, when guiding EPS and market cap.

Technique decision table

Vehicle	Speed	Typical discount	Retail-friendly?	Best when
Rights offering	Slow (3–6 weeks)	10–20% subscription	High if holders exercise	Fairness narrative, weak marketed demand, REIT/bank recap
Overnight follow-on	Fast (1–2 days)	3–8% to unaffected	Low (institutional book)	Window open, large liquid issuer, urgent capital
ATM program	Dribble over months	Minimal (at market)	Neutral	Stealth primary, volatile stock, shelf flexibility
Convertible notes	Medium	Coupon + conversion premium	Low	Deferred dilution, tax shield, growth optionality
Investment-grade debt	Medium	N/A (no equity)	N/A	Cash flow covers coupon, leverage headroom
Buyback	Flexible	N/A (retires shares)	Indirect	Excess cash, undervalued stock, no growth capex need

Common pitfalls

Assuming 100% take-up in models — passive funds and retail lapse rates of 25–40% are normal; guide EPS on partial exercise.
Missing the ex-rights date — buying stock on ex-date without rights gives no subscription; selling before ex-date forfeits rights unless you exercise first.
Ignoring oversubscription — fully exercising holders can often buy more at the discount when others lapse.
Selling rights into illiquid markets — wide spreads erode value; compare net proceeds to exercise economics.
Underestimating backstop fees — weak take-up shifts cost from spread to backstop; all-in issuance cost can exceed a follow-on.
Confusing rights with warrants — rights expire; warrants have longer lives and different terms.
Tax surprises — lapsing rights may be a taxable event in some jurisdictions; consult a tax advisor for non-US holders.
Charter limits — some companies need shareholder votes to authorize sufficient authorized shares before launching.

Shareholder and issuer checklist

Read the prospectus supplement for ratio, subscription price, and expiration.
Mark record date, ex-rights date, and subscription deadline on your calendar.
Calculate theoretical right value and compare exercise vs sell-rights vs do nothing.
Exercise basic rights before considering oversubscription allocation.
Confirm broker instructions settle before expiration (T+1 timing matters).
Model your ownership under partial take-up, not only full participation.
Issuers: size backstop for realistic lapse rates; disclose fee stack transparently.
Issuers: run retail education (email, FAQ) — lapse rates drop with outreach.
Update fully diluted share count and EPS guidance post-settlement.
Compare all-in cost to alternative vehicles (follow-on, ATM, convert) before signing.

Key takeaways

Rights offerings give existing shareholders first crack at new shares at a discount — but only exercising (or selling rights) captures that value.
Record date, ex-rights date, and subscription period define who gets rights and when the stock price adjusts.
Partial take-up is normal; standby underwriters backstop lapses but add fees that raise all-in issuance cost.
Non-participants are diluted more than participants; oversubscription lets attentive holders buy lapsed shares at the subscription price.
Harbor Biotech raised $95M with 62% exercise and $4.2M in backstop fees — fair for retail who acted, costly for those who slept through the window.